Latest Insights - page 18 | BiopharmaTrend

BenchSci and Thermo Fisher Collaborate to Develop AI Tools for Preclinical R&D

Toronto-based BenchSci has entered a strategic partnership with Thermo Fisher Scientific to create AI-powered tools aimed at improving experimental design, reagent selection, and overall R&D productivity. The collaboration combines BenchSci’s …

Continue ›››

Why AI Needs to Be at the Center of mRNA Design

One of the biggest hurdles in mRNA development is the in vitro to in vivo gap; results that look strong in lab models often fail to translate in living systems. …

Continue ›››

Human Cells Edited at Megabase Scale With Bridge Recombinases

Researchers report in Science a genome-editing approach that rearranges long stretches of human DNA—insertions, deletions, and inversions—within regions up to about one megabase (with demonstrations of ~920 kb inversions and …

Continue ›››

AI Framework Produces Functional Nanobodies with Reduced Screening

A new preprint from the Brian Hie and Xiaojing Gao labs, in collaboration with the Arc Institute, introduces Germinal, a generative AI framework designed to accelerate antibody creation. Applied to …

Continue ›››

Aera Reports Preclinical Data on Lipid Nanoparticle-Delivered In Vivo CAR-T Therapy

Aera Therapeutics has presented preclinical results and nominated AERA-109, its first development candidate, for B cell–mediated autoimmune diseases. The candidate is built on the company’s targeted lipid nanoparticle (tLNP) delivery …

Continue ›››

How Tech Giants like NVIDIA, Google, and Microsoft Are Targeting New Niches in Biopharma R&D

Tech giants are becoming part of biopharma’s infrastructure, applying AI, data, and cloud to drug discovery as they seek footholds in new markets. Large technology companies aren’t newcomers to biopharma …

Continue ›››

Proscia and Pictor Labs Bring AI-Powered Virtual Staining to Digital Pathology

Proscia, a digital pathology software company, has announced that its Concentriq platform will now include virtual staining capabilities powered by Pictor Labs. The integration is aimed at reducing reliance on …

Continue ›››

Healx Expands Rare Oncology Pipeline Through AI-centered Deal with Vuja De Sciences

Healx, a drug discovery company founded by Tim Guilliams, a Cambridge-trained tech entrepreneur, and David Brown, the co-inventor of Viagra, has entered into a strategic collaboration with Vuja De Sciences …

Continue ›››

Pi Health and GSK Sign Agreement for AI-Driven Clinical Trial Collaboration

Pi Health has entered into a collaboration with GSK to deliver fully outsourced clinical research services for a global Phase 2 oncology trial (undisclosed at this moment). The agreement is …

Continue ›››

uniQure Reports Trial Success for Experimental Huntington’s Disease Gene Therapy

uniQure has announced positive topline results from its Phase I/II study of AMT-130, an experimental gene therapy for Huntington’s disease. Patients receiving the high dose showed a 75% slowing of …

Continue ›››

DaltonTx Secures £4 Million Seed Funding to Develop Adaptive AI for Drug Discovery

DaltonTx, a UK-based technology company co-founded by Dr. Garry Pairaudeau, Adrian Rossall, Dr. Anthony Bradley, and Professor Charlotte Deane MBE, has emerged from stealth with £4 million in seed financing …

Continue ›››

Sanofi Expands Corporate Venture Fund With $625 Million Commitment

Sanofi has allocated an additional $625 million to Sanofi Ventures, bringing the corporate venture arm’s total assets under management to over $1.4 billion. The evergreen fund, active since 2012, will …

Continue ›››